Literature DB >> 11503959

Hematopoietic capability of CD34+ cord blood cells: a comparison with CD34+ adult bone marrow cells.

Takahiro Ueda1,2, Makoto Yoshida3, Hiroshi Yoshino1, Kimio Kobayashi4, Mariko Kawahata4, Yasuhiro Ebihara1, Mamoru Ito4, Shigetaka Asano1,5, Tatsutoshi Nakahata6, Kohichiro Tsuji7.   

Abstract

The characteristics of hematopoietic progenitor and stem cell (HPC/HSC) populations in mammals vary according to their ontogenic stage. In humans, HPC/HSCs from umbilical cord blood (CB) are increasingly used as an alternative to HPC/HSCs from adult bone marrow (BM) for the treatment of various hematologic disorders. How the hematopoietic activity of progenitor and stem cells in CB differs from that in adult BM remains unclear, however. We compared CD34+ cells, a hematopoietic cell population, in CB with those in adult BM using phenotypic subpopulations analyzed by flow cytometry, the colony-forming activity in methylcellulose clonal cultures, and the repopulating ability of these cells in NOD/Shi-scid (NOD/SCID) mice. Although the proportion of CD34+ cells was higher in adult BM than in CB mononuclear cells, the more immature subpopulations, CD34+ CD33- and CD34+ CD38- cells, were present in higher proportions in CD34+ CB cells. Clonal culture assay showed that more multipotential progenitors were present in CD34+ CB cells. When transplanted into NOD/SCID mice. CD34+ adult BM cells could not reconstitute human hematopoiesis in recipient BM, but CD34+ CB cells achieved a high level of engraftment, indicating that CD34+ CB cells possess a greater repopulating ability. These results demonstrated that human hematopoiesis changes with development from fetus to adult. Furthermore, CD34+ CB cells contained a greater number of primitive hematopoietic cells, including HSCs, than did adult BM, suggesting the usefulness of CD34+ CB cells not only as a graft for therapeutic HSC transplantation but also as a target cell population for ex vivo expansion of transplantable HSCs and for gene transfer in gene therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11503959     DOI: 10.1007/BF02994007

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells.

Authors:  O I Gan; B Murdoch; A Larochelle; J E Dick
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

Review 2.  Self-renewal and migration of stem cells during embryonic and fetal hematopoiesis: important, but poorly understood events.

Authors:  H E Broxmeyer
Journal:  Blood Cells       Date:  1991

3.  Cell adhesion molecules in cord blood hematopoietic progenitors.

Authors:  F Timeus; N Crescenzio; D Marranca; M Dall'Aglio; L Fazio; M Di Marco; P Saracco; M Ricotti; V Gabutti
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

4.  Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo.

Authors:  M A Moore; D Metcalf
Journal:  Br J Haematol       Date:  1970-03       Impact factor: 6.998

5.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

Authors:  M Bhatia; J C Wang; U Kapp; D Bonnet; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  The repopulation potential of fetal liver hematopoietic stem cells in mice exceeds that of their liver adult bone marrow counterparts.

Authors:  V I Rebel; C L Miller; C J Eaves; P M Lansdorp
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

7.  Hematopoietic repopulating ability of cord blood CD34(+) cells in NOD/Shi-scid mice.

Authors:  T Ueda; H Yoshino; K Kobayashi; M Kawahata; Y Ebihara; M Ito; S Asano; T Nakahata; K Tsuji
Journal:  Stem Cells       Date:  2000       Impact factor: 6.277

8.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy.

Authors:  A Larochelle; J Vormoor; H Hanenberg; J C Wang; M Bhatia; T Lapidot; T Moritz; B Murdoch; X L Xiao; I Kato; D A Williams; J E Dick
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

9.  Unrelated umbilical cord-blood stem cell transplantation: a report from Kanagawa Cord Blood Bank, Japan.

Authors:  H Nishihira; K Ohnuma; K Ikuta; K Isoyama; A Kinoshita; Y Toyoda; M Ohira; J Okamura; F Nakajima
Journal:  Int J Hematol       Date:  1998-08       Impact factor: 2.490

10.  gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells.

Authors:  X Sui; K Tsuji; R Tanaka; S Tajima; K Muraoka; Y Ebihara; K Ikebuchi; K Yasukawa; T Taga; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more
  10 in total

Review 1.  Ex vivo expansion of human hematopoietic stem and progenitor cells.

Authors:  Ann Dahlberg; Colleen Delaney; Irwin D Bernstein
Journal:  Blood       Date:  2011-03-23       Impact factor: 22.113

Review 2.  The niche as a target for hematopoietic manipulation and regeneration.

Authors:  Rialnat A Lawal; Laura M Calvi
Journal:  Tissue Eng Part B Rev       Date:  2011-09-27       Impact factor: 6.389

3.  Effects of dendritic cells from cord blood CD34+ cells on human hepatocarcinoma cell line BEL-7402 in vitro and in SCID mice.

Authors:  Zhong-Jing Su; Hai-Bin Chen; Jin-Kun Zhang; Lan Xu
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

4.  Tunica interna endothelial cell kinase expression and hematopoietic and angiogenic potentials in cord blood CD34+ cells.

Authors:  Mika Wada; Yasuhiro Ebihara; Feng Ma; Hiroshi Yagasaki; Mamoru Ito; Tsuneo Takahashi; Hideo Mugishima; Shigeru Takahashi; Kohichiro Tsuji
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

5.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

Review 6.  Establishing humanized mice using stem cells: maximizing the potential.

Authors:  D Bernard; M Peakman; A C Hayday
Journal:  Clin Exp Immunol       Date:  2008-04-24       Impact factor: 4.330

7.  Genetic Comparison of Stemness of Human Umbilical Cord and Dental Pulp.

Authors:  Chung-Min Kang; Hyunok Kim; Je Seon Song; Byung-Jai Choi; Seong-Oh Kim; Han-Sung Jung; Seok-Jun Moon; Hyung-Jun Choi
Journal:  Stem Cells Int       Date:  2016-03-21       Impact factor: 5.443

8.  Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.

Authors:  Sherin Bakhashab; Fahad W Ahmed; Hans-Juergen Schulten; Ayat Bashir; Sajjad Karim; Abdulrahman L Al-Malki; Mamdooh A Gari; Adel M Abuzenadah; Adeel G Chaudhary; Mohammed H Alqahtani; Sahira Lary; Farid Ahmed; Jolanta U Weaver
Journal:  Cardiovasc Diabetol       Date:  2016-02-09       Impact factor: 9.951

9.  Effects of Osteogenic-Conditioned Medium from Human Periosteum-Derived Cells on Osteoclast Differentiation.

Authors:  Hyun-Chang Park; Young-Bum Son; Sung-Lim Lee; Gyu-Jin Rho; Young-Hoon Kang; Bong-Wook Park; Sung-Hoon Byun; Sun-Chul Hwang; In-Ae Cho; Yeong-Cheol Cho; Iel-Yong Sung; Dong Kyun Woo; June-Ho Byun
Journal:  Int J Med Sci       Date:  2017-11-02       Impact factor: 3.738

10.  Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients.

Authors:  Melanie Werner-Klein; Judith Proske; Christian Werno; Katharina Schneider; Hans-Stefan Hofmann; Brigitte Rack; Stefan Buchholz; Roman Ganzer; Andreas Blana; Birgit Seelbach-Göbel; Ulrich Nitsche; Daniela N Männel; Christoph A Klein
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.